 |
|
Maximum: 1 CME cr.,
1 AutoAttendance cr.
Sign in to view your progression
|
Activity Title: HIV Hot Topics
Release Date: March 8, 2022
Estimated Time to Complete Activity: 70 minutes
Statement of Need: This session reviews the progress for HIV treatment expansion on a global scale, the timing of initiation of antiretroviral therapy, and provides updates on pre-exposure prophylaxis. Researchers present data with associated outcomes on recent interventions that identify and provide treatment and prevention programs to at-risk populations residing in low- and middle-income countries. Additionally, attention is devoted to HIV-related stigma and discrimination in healthcare settings and how to provide equitable access to HIV prevention and care.
Faculty:
Prof. Jennifer Hoy, Australia
What’s New in Antiretroviral Therapy (ART)
Associate Prof. Raja Iskandar Shah Raja Azwa, Malaysia
Pre-Exposure Prophylaxis (PrEP) Updates
Dr. Rayner Tan, Singapore
HIV Stigma in Healthcare Settings
Technical Requirements
This site and its activities are best viewed using the latest versions of Chrome, Edge, Firefox, and Safari browsers. For interactive content, a broadband connection is required. For CME/CE activities featuring audio, you need a sound card and speakers.
Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.
Contact Information
If you have questions about this CME activity, please contact The International Society for Infectious Diseases at info@isid.org.
For technical support issues, please contact Multilearning at support@multilearning.com
Upon completion of this module, participants should be able to:
- Describe the progress of HIV treatment expansion on a global scale
- Understand the timing of initiation of antiretroviral therapy
- Discuss updates on pre-exposure prophylaxis.
- Discuss data with associated outcomes of recent interventions that identify and provide treatment and prevention programs to at-risk populations
- Understand HIV-related stigma and discrimination in healthcare settings
- Implement learned strategies to provide equitable access to HIV prevention and care
Physicians, nurses, public health officials, researchers, and other health professionals
WHO: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach (2021). https://www.who.int/publications/i/item/9789240031593
PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES – 2021 UPDATE. A CLINICAL PRACTICE GUIDELINE. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
Commissioners of and collaborators with the International AIDS Society–Lancet Commission on Health and Human Rights. Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights. Lancet. 2021 Apr 24;397(10284):1524-1527. doi: 10.1016/S0140-6736(21)00708-X. Epub 2021 Mar 24. PMID: 33773117; PMCID: PMC7990478. https://pubmed.ncbi.nlm.nih.gov/33773117/
Lazarus JV, Safreed-Harmon K, Kamarulzaman A, Anderson J, Leite RB, Behrens G, Bekker LG, Bhagani S, Brown D, Brown G, Buchbinder S, Caceres C, Cahn PE, Carrieri P, Caswell G, Cooke GS, Monforte AD, Dedes N, Del Amo J, Elliott R, El-Sadr WM, Fuster-Ruiz de Apodaca MJ, Guaraldi G, Hallett T, Harding R, Hellard M, Jaffar S, Kall M, Klein M, Lewin SR, Mayer K, Pérez-Molina JA, Moraa D, Naniche D, Nash D, Noori T, Pozniak A, Rajasuriar R, Reiss P, Rizk N, Rockstroh J, Romero D, Sabin C, Serwadda D, Waters L. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nat Commun. 2021 Jul 16;12(1):4450. doi: 10.1038/s41467-021-24673-w. PMID: 34272399; PMCID: PMC8285468. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285468/
Hempel S, Ferguson L, Bolshakova M, Yagyu S, Fu N, Motala A, Gruskin S. Frameworks, measures, and interventions for HIV-related internalised stigma and stigma in healthcare and laws and policies: systematic review protocol. BMJ Open. 2021 Dec 9;11(12):e053608. doi: 10.1136/bmjopen-2021-053608. PMID: 34887280; PMCID: PMC8663079. https://bmjopen.bmj.com/content/11/12/e053608.long
Disclosure Policy
In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Activity Staff Disclosures:
The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose.
ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here along with Committee members’ disclosure forms.
Faculty Disclosures:
Jennifer Hoy
Her institution has received reimbursement for my time on Advisory Boards for Gilead Sciences and ViiV Healthcare
Raja Iskandar Shah Raja Azwa has no potential conflict of interest to report
Rayner Tan has no potential conflict of interest to report
Moderator Disclosures:
Adeeba Kamarulzaman,
Organization- Relationship
amfAR - Research grant Universiti Malaya
OSF - Program & Research grant Universiti Malaya
ViiV - Program support Malaysian AIDS Foundation
Gilead - Program support Universiti Malaya Medical Centre
Malaysian AIDS Foundation - Chait
ROSE Foundation- Chair
Fogarty, NIH - Institutional training grants Universiti Malaya
NIDA - Research grants
Zuellig Pharma - Investigator-initiated grand support
Allianz Insurance - Investigator-initiated grand
Johnson & Johnson - Member, Scientific Advisory Board
Roche - Member, Scientific Advisory Board
Valneva -Member, Scientific Advisory Board
Frontiers Biotech -Member, Scientific Advisory Board
Seif Al-Abri has no potential conflict of interest to report
Disclosure of Unlabeled Use
The International Society for Infectious Diseases requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.
Copyright Information
Copyright © 2021 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.
Privacy Policy
The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at https://isid.org/privacy-policy/ and https://exchange.isid.org/isid/legal/terms-and-conditions.
|
ACCREDITED ACTIVITY
HIV - Hot Topics 2022
|
|
